GCC Agonist Signal in the Small Intestine
Pilot Study of GCC Agonists to Identify a Cyclic-GMP Signal in Duodenal Tissue of Volunteers
Sponsor: National Cancer Institute (NCI)
A PHASE1 clinical study on Barrett Esophagus and Gastroesophageal Reflux Disease, this trial is ongoing. The trial is conducted by National Cancer Institute (NCI) and has accumulated 15 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
15 versions recorded-
Jan 2026 — Present [monthly]
Active Not Recruiting PHASE1
-
Nov 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE1
-
Jun 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Jun 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
▶ Show 10 earlier versions
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE1
-
Nov 2023 — May 2024 [monthly]
Recruiting PHASE1
Phase: EARLY_PHASE1 → PHASE1
-
Nov 2022 — Nov 2023 [monthly]
Recruiting EARLY_PHASE1
Status: Not Yet Recruiting → Recruiting
-
Oct 2022 — Nov 2022 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Sep 2022 — Oct 2022 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Jul 2022 — Sep 2022 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Jun 2022 — Jul 2022 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Feb 2022 — Jun 2022 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Dec 2021 — Feb 2022 [monthly]
Not Yet Recruiting EARLY_PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- University of Wisconsin, Madison
For direct contact, visit the study record on ClinicalTrials.gov .